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ABSTRACT
Background Assembly of cytochrome c oxidase (COX,
complex IV, cIV), the terminal component of the
mitochondrial respiratory chain, is assisted by several
factors, most of which are conserved from yeast to
humans. However, some of them, including COA7, are
found in humans but not in yeast. COA7 is a 231aa-
long mitochondrial protein present in animals, containing
five Sel1-like tetratricopeptide repeat sequences, which
are likely to interact with partner proteins.
Methods Whole exome sequencing was carried out on
a 19 year old woman, affected by early onset,
progressive severe ataxia and peripheral neuropathy, mild
cognitive impairment and a cavitating leukodystrophy of
the brain with spinal cord hypotrophy. Biochemical
analysis of the mitochondrial respiratory chain revealed
the presence of isolated deficiency of cytochrome c
oxidase (COX) activity in skin fibroblasts and skeletal
muscle. Mitochondrial localization studies were carried
out in isolated mitochondria and mitoplasts from
immortalized control human fibroblasts.
Results We found compound heterozygous mutations
in COA7: a paternal c.410A>G, p.Y137C, and a
maternal c.287+1G>T variants. Lentiviral-mediated
expression of recombinant wild-type COA7 cDNA in the
patient fibroblasts led to the recovery of the defect in
COX activity and restoration of normal COX amount. In
mitochondrial localization experiments, COA7 behaved
as the soluble matrix protein Citrate Synthase.
Conclusions We report here the first patient carrying
pathogenic mutations of COA7, causative of isolated
COX deficiency and progressive neurological impairment.
We also show that COA7 is a soluble protein localized
to the matrix, rather than in the intermembrane space as
previously suggested.
INTRODUCTION
Cytochrome c oxidase (COX) is the terminal com-
ponent of the mitochondrial respiratory chain
(MRC). COX transfers four electrons from cyto-
chrome c to oxygen. The energy liberated by this
redox reaction sustains the translocation of four
protons from the matrix to the intermembrane
space (IMS) and contributes to the formation of
the mitochondrial electrochemical gradient. In
humans, COX deficiency can be either isolated or
combined to defects in other MRC complexes.
Phenotypes may vary1 2 from multisystem disorders
to isolated myopathies or encephalopathies.3 4
Isolated COX deficiency may be caused by
mutations in mitochondrial DNA (mtDNA) or
nuclear DNA genes encoding structural COX subu-
nits, but in most cases is due to recessive mutations
in nuclear genes encoding factors involved in COX
biogenesis.5 COA7 is a putative COX assembly
factor containing five Sel1-like repeat domains
(Interpro IPR006597), is conserved in animals, but
neither in plants nor in fungi, and has been
reported to localise in the mitochondrial IMS.6
Here, we describe the first biallelic pathogenic
COA7 mutations in a patient with isolated COX
deficiency and leukoencephalopathy, and show that
the protein is localised in the inner mitochondrial
compartment, predominantly in the matrix.
CASE REPORT
The proband is a 19-year-old woman, first child of
healthy unrelated parents. Her family history was
unremarkable. She was born at term after a normal
pregnancy. The perinatal period was uneventful
and her early development was referred to as
normal, but after 1 year of age, psychomotor delay
became evident. She started walking autonomously
at 22 months, with poor balance and frequent falls.
At 3 years of age, she developed a demyelinating
sensorimotor neuropathy and a brain MRI dis-
closed supratentorial leukodystrophy. During her
childhood, the clinical signs remained stable. At
10 years, her walking difficulties worsened, and
limb weakness and tremor ensued. The neuro-
logical evaluation showed dysarthria, dysmetria,
ataxic gait and hyporeflexia in the four limbs with
muscle wasting. She was able to walk alone only
for a few steps with an ataxic gait. Mild cognitive
impairment was documented (IQ 75, WISC-R
scale). Histological analysis of a muscle biopsy
showed hypo/atrophy of fibres. The clinical evolu-
tion was slowly progressive. At her last follow-up
examination, at 19 years of age, she was able to
walk alone only with ankle-foot orthotic aids and
had developed a marked dorsal-lumbar scoliosis.
Other clinical signs were stable. Neurophysiological
studies confirmed worsening of her mixed axonal
demyelinating peripheral neuropathy. Brain and
spinal cord MRI showed mild extension of signal
abnormalities and extensive cavitations in the cere-
bral white matter; the cerebellum and brainstem
were spared but the spinal cord was thin with no
obvious focal lesions (figure 1A). Plasma lactate
was 2.9 mM (n.v. <2.1).
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METHODS
Whole exome sequencing (WES) was performed as described.7
Fibroblasts from skin biopsies were immortalised by lentiviral
transduction using the pLOX-Ttag-iresTK vector (Tronolab,
Addgene #12246). Primary and immortalised fibroblasts and
HEK293T cells were grown in standard conditions. For mitochon-
drial localisation studies, mitochondria and mitoplasts were prepared
and trypsin-digested as previously described.8 9 For membrane asso-
ciation studies, sonicated mitochondrial supernatants containing the
soluble fractions were separated from the membrane-enriched
pellets by ultracentrifugation. Membrane-containing pellets were
treated with increasing ionic strength buffers, and for the final
protein dissociation, they were suspended in equal volumes of iso-
tonic buffer containing 0.2% SDS. These fractions were analysed by
western-blot (WB) immunodetection, using several proteins as
markers of distinct mitochondrial compartments.
The COA7 cDNA sequence was obtained from the IMAGE
clone (ID: 4430419/IRATp970-0D0921D). PCR products were
cloned into the lentiviral vector pWPXLd-ires-PuroR (derived from
pWPXLd, Tronolab, Addgene #12258). Lentiviral particle produc-
tion and transduction of target cells were performed as recom-
mended (https://www.addgene.org/tools/protocols/plko/#E).
Sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) and blue native gel electrophoresis (BNGE) were
performed as described.10 Antibodies were purchased from
Proteintech, Abcam and Sigma.
MRC and other enzymatic activities were measured as
described.11 12
RESULTS
Biallelic mutations in COA7 are present in the proband
This study was approved by the Ethical Committee of the ‘Carlo
Besta’ Neurological Institute, Milan, Italy, in agreement with the
Declaration of Helsinki. Informed consent was signed by the
parents of the patient. We ruled out the presence of pathogenic
mutations in mtDNA by Sanger sequencing. WES7 was then
carried out. After standard filtering steps and assuming a recessive
trait, we prioritised 13 genes with either one homozygous variant
or two heterozygous variants. Of these 13 genes, the only one
encoding a mitochondria-targeted protein was COA7,6 which
carried a (paternal) heterozygous nucleotide transition c.410A>G
(NM_023077), p.Y137C and a (maternal) heterozygous G>T
transversion affecting the first intronic nucleotide of the exon 2/
intron 2 junction (c.287+1G>T). The two variants were not
reported in the ExAc database (March 2016). The presence of both
mutations was validated by Sanger sequencing.
COA7 mutations are associated with absence of the COA7
protein
Amplification of the patient COA7 cDNA yielded two bands.
The upper band, which had the same size as that amplified from
control samples, showed the c.410A>G paternal missense muta-
tion. The lower band was originated from the maternal allele
containing the c.287+1G>T-splicing mutation, which produces
the deletion of the whole 141bp-long exon 2 of COA7 (figure
1B). The missense mutation affects the highly conserved Tyr137,
which is replaced by a non-conservative Cys residue, whereas
the splice site mutation produces the in-frame deletion of the 47
amino acids encoded by exon 2. This deletion spans almost all
of the first conserved Sel1-like domain and half of the second
(figure 1C).
Next, total protein lysates extracted from patient-derived cells
were analysed by WB using a specific anti-COA7 antibody. No
COA7 cross-reacting material was immunodetectable, and the
amount of two COX structural subunits (MT-CO2 and
Figure 1 Clinical and genetic findings. (A) Transverse supratentorial (i), coronal (ii) and sagittal brain/spinal cord (iii) T2- fluid attenuated inversion
recovery (FLAIR) MRI sequences. (B) Sanger sequence of the mutated regions in cDNA from mutant fibroblasts. (C) Clustal W diagram. Boxed areas
correspond to mutations. Sel1-like conserved domains are underlined.
Martinez Lyons A, et al. J Med Genet 2016;53:846–849. doi:10.1136/jmedgenet-2016-104194 847
Mitochondrial genetics
MT-CO3) was reduced in the mutant sample, relative to control
cells, whereas that of subunits belonging to complex I and
complex III was normal (figure 2A).
COX activity and assembly are recovered after expression of
wild-type COA7
In patient-derived immortalised fibroblasts, the levels of fully
assembled cIV and of the cIII2+cIV supercomplex were clearly
lower relative to controls (figure 2B).
In order to test complementation, wild-type (wt) COA7
(COA7wt) was transduced in immortalised mutant fibroblasts.
Robust overexpression of COA7wt was detected in both mutant
and wt transduced cells, and, in mutant cells, this was associated
with the recovery of normal amount of MT-CO2 subunit
(figure 2C) and of both COX assembly (figure 2D) and activity
(figure 2E).
COA7 is localised in the mitochondrial matrix
To further characterise COA7, we isolated mitochondria from
HEK293T cells and performed WB analysis in organellar and
suborganellar fractions. Trypsin digestion was carried out in both
intact mitochondria or after stripping off the outer mitochondrial
membrane (mitoplasts), by either hypotonic shock or digitonin
treatment. The outer membrane protein TOM70 was completely
digested by trypsin in mitochondria and mitoplasts; the IMS
protein cytochrome c was protected in mitochondria but progres-
sively digested in mitoplasts, whereas the inner membrane
protein succinate dehydrogenase subunit A (SDHA) (part of cII)
and the matrix protein citrate synthase were protected from
digestion in both mitochondria and mitoplasts, as was COA7
(figure 2F). Next, mitochondria were disrupted by sonication,
and the ionic strength was increased by adding NaCl to soluble
versus membrane fractions. As shown in figure 2G, COA7 was
predominantly immunodetected in the supernatant, similar to
citrate synthase, although a small percentage was also detected in
the pellet, before SDS treatment. Taken together, these results
indicate that COA7 is predominantly localised in the mitochon-
drial matrix, although a small aliquot appears to be associated
with the inner mitochondrial membrane.
DISCUSSION
COA7 is involved in MRC biogenesis, as depletion by RNAi in
cultured cells clearly affected COX assembly.6 Here, we present
the first pathological mutations in COA7 in humans, associated
with a severe, slowly progressive mitochondrial neurological dis-
order. We found biallelic mutations in one patient, according to
the autosomal recessive mode of inheritance suggested by the
patient’s family tree. The COA7 mRNA skipping of exon 2 in
the maternal allele and the drastic amino acid change in the
paternal allele suggested pathogenicity. Indeed, WB
Figure 2 Western blot (WB) immunodetection and enzymatic activities. (A) WB immunodetection of SDS-PAGE in primary fibroblasts. P, patient,
C1 and C2, control cell lines. (B) WB immunodetection of BNGE in immortalised patient (Pi) and control (C3i) fibroblasts. Immunovisualised subunits
are between brackets. (C) WB immunodetection of SDS-PAGE in immortalised patient fibroblasts (Pi) and a control (C4i). n.t., not transduced; mock,
transduced with empty vector; COA7, transduced with COA7. (D) WB immunodetection of BNGE in COA7-transduced immortalised fibroblasts from
patient (Pi) and a control (C4i). (E) Cytochrome c oxidase (COX)/citrate synthase (CS) activity in immortalised fibroblasts of two controls (C3i, C4i),
and the patient (Pi). Vertical bars indicate SEM. Statistical analysis was by ANOVA (*p<0.05; **p<0.01; ***p<0.001). (F) WB immunodetection of
SDS-PAGE of mitochondria and mitoplasts from HEK293T cells. (G) WB immunodetection of SDS-PAGE of soluble and membrane fractions from
intact mitochondria. ANOVA, analysis of variance.
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immunodetection showed the virtual absence of the protein in
cultured cells. Furthermore, the expression of COA7wt restored
COX assembly and activity in mutant cells.
Our case was diagnosed as a mitochondrial encephalopathy
and peripheral neuropathy. Although the onset was in infancy,
the clinical course was slowly progressive, as the patient has
reached adulthood in relatively stable conditions. This could be
related to a partially dispensable role of COA7 in COX
biogenesis.
Finally, our suborganellar fractionation studies, supported by
in vitro import results, indicate that COA7 localises in the mito-
chondrial inner compartment, mostly in the matrix, rather than
in the IMS, as previously proposed.6 We suggest that the pro-
posed localisation to the IMS was in fact the consequence of a
incorrect interpretation of results similar to ours, that is, protec-
tion of COA7 from proteinase K-treated mitoplasts, thus
indicating its localisation within the inner mitochondrial
compartment.6
Future work is warranted to establish the interactions and
partners of COA7, its mechanisms of action and the steps of its
intervention during the formation of COX.
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